Vyne Therapeutics‘ experimental inhaled therapy VYN201 led to significant reductions in lung fibrosis and improvements in lung function in a mouse model of idiopathic pulmonary fibrosis (IPF), the company announced. “The data from this well-validated preclinical model of IPF clearly demonstrates VYN201’s potential to deliver a potent anti-inflammatory…
Inhaled IPF therapy VYN201 eases fibrosis in mouse model
A high dose of bexotegrast, an oral treatment being developed by Pliant Therapeutics, continues to be well-tolerated for up to about nine months, with no serious side effects in people with idiopathic pulmonary fibrosis (IPF), according to long-term data from a Phase 2a trial. Six-month data from the…
Michel de Notredame, more commonly known as Nostradamus, was a French astrologer, physician, and to many, seer. He recorded his prophecies in the 16th-century book “Centuries,” and some consider his view of the future incredibly accurate. More recently, Eric Arthur Blair, using the pen name George…
Innovate UK has awarded biotechnology company Senisca £571,350 (about $712,000) to develop oligonucleotide treatments for idiopathic pulmonary fibrosis (IPF). The UK-based company is working on innovative biologic treatments that use oligonucleotides — short strands of RNA or DNA — to reverse senescence in IPF-specific tissues. Senescence, which…
I regularly pick up and read my journal from the early days after my diagnosis of idiopathic pulmonary fibrosis (IPF). I’ve shared some of those thoughts in earlier columns. The entries aren’t that different from other people’s journals, and some are intimate thoughts intended only for me. The…
The first participant has been dosed in a clinical trial testing the experimental anti-fibrotic therapy BBT-877 in people with idiopathic pulmonary fibrosis (IPF). The milestone was announced by BBT-877’s developer Bridge Biotherapeutics, which initiated the trial late last year. “The first patient dosing of BBT-877 marks an…
Dealing with the financial expenses associated with having a rare or chronic illness like pulmonary fibrosis (PF) can be tough. I’m responsible for making sure that I receive all the PF treatments available to me, but I’ve discovered that they come with a hefty price tag. Among the…
American comedian Bill Engvall is known for his punchline “Here’s your sign,” which he’d often say in response to an outrageously obvious question. I recently experienced two “here’s your sign” moments of my own after wondering if I’d contracted the virus that causes COVID-19. On Monday, April 3, I…
One-year of high-dose AP01, Avalyn Pharma’s inhaled pirfenidone solution, slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF). That’s according to top-line data from the ongoing open-label extension AP01-005 study (2020-005103-39) that’s testing a 100 mg high dose of AP01, administered twice daily. The results align…
By the end of this month, the Pulmonary Fibrosis Foundation (PFF) is hoping to bump up patient and caregiver enrollment — by at least 500 people — in its pulmonary fibrosis (PF) community registry. April is PFF Community Registry Recruitment Month, and the foundation is trying to…
